Liver Fluke Treatment Market

Liver Fluke Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment; 2018 – 2028

  • Ongoing
  • January 2020
  • REP-GB-9298
  • PDF PPT EXCEL
Liver Fluke Treatment Market
  • SELECT LICENSE TYPE :

  • US$5,000
  • US$7,500
  • US$10,000

This Liver Fluke Treatment market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Liver Fluke Treatment market.


Liver Fluke is defined by the condition affected by the infection causing worms. The liver fluke is generally categorized in 2 types by infection causing worms and termed as Fasciola hepatica and Fasciola gigantica. Many a times the liver fluke infection goes undiagnosed or misdiagnosed with common abdominal pain. The liver fluke denies the pathway of common worm’s infection transmitting from one person another. The available liver fluke treatment is based on the anthelmintic effects the drug exert in the body. Another liver fluke treatment line is permitted by the government and CDC is oral triclabendazole where’s the WHO have listed he drug as an essential drug and it is still not approved in some parts of US. The liver fluke treatment regimen also follows the use of the Bithionol and nitazoxanide for the removal of worms for the liver although a surgical intervention and in some cases a worm removal surgery is essential due to infection to bile duct.

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Need granular data and specific insights that are hard to get?

Liver Fluke Treatment Market: Drivers and Restraints

Rapidly expanding research studies and growing incidence of infection in humans and cattle. Research on the development of the dedicated drug for Liver Fluke Treatment following with increasing availability of Symptomatic Liver Fluke Treatment. Is anticipated to fuel the Liver Fluke Treatment market. Furthermore, government organization on raising awareness on liver fluke, fascioliasis and Liver Fluke Treatment drug is signifying the growth of the Liver Fluke Treatment market. The surge in the fascioliasis prevalence and incidence rate is estimated as the major factor for the growth of the Liver Fluke Treatment market owing to the higher rate of liver fluke in wetlands and related emergency room visits. The essential medicine status for the Liver Fluke Treatment drug triclabendazole is anticipated to offer new growth opportunities for the Liver Fluke Treatment market. However, complexity in dose preparation and adjustment for Liver Fluke Treatment drugs and requirement of long treatment cycles is anticipated the restraint the growth of the Liver Fluke Treatment market.

Liver Fluke Treatment Market: Overview

The Liver Fluke Treatment market displays the monopoly of single manufacturer and are primarily focused on delivering free medicines under the WHO tie up with the manufacturer. As per the data from the Novartis approximately 41 million worth of drug is donated and utilized by the 2 million people all around the world. The drug provided by the Novartis Egaten is the only approved medication for the of liver fluke treatment in human can animals although a veterinary substitute is available for the triclabendazole. Egaten is the widely used medication and listed in the WHO model essential medicines list. The liver fluke is more prevalent in the developing regions and wetland due to poor sanitary conditions. The growing intensity of the infection spread is anticipated to fuel the demand for liver fluke treatment drug. Subsequently aiding to increase the liver fluke treatment market. Due to rare nature of infection and government aid new manufacturers are queuing up for the entry in the liver fluke treatment market.

Liver Fluke Treatment Market: Region-Wise Overview

The global Liver Fluke Treatment market is segmented into the following regions - North America, Latin America, Europe, East Asia, south Asia, Oceania and the Middle East & Africa. East Asia is the leading regional market for Liver Fluke Treatment due to the increasing incidence of liver fluke, fasciola hepatica. Additionally symptomatic Liver Fluke Treatment demand in the region. In East Asia, china is dominating Liver Fluke Treatment market due to increasing awareness for fasciola hepatica and rising beef and seafood use in the country. Latin America Liver Fluke Treatment market is anticipated to grow significantly higher owing to higher incidence in Peru and Bolivia. South Asia is a growing at significant rate owing to growing awareness initiatives form government in Liver Fluke Treatment. Growth in North America and the Europe is considerably low due to low incidence rate and higher sanitization parameters in the regions.

Liver Fluke Treatment Market: Key Participants

Examples of some of the key participants in the Liver Fluke Treatment market are Novartis, GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc, Bayer HealthCare Pharmaceuticals Inc., Par Pharmaceutical, Romark Laboratories, L.C., Lupin Pharma, Schering Corporation among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also includes projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

  • Liver Fluke Treatment Market Segments
  • Liver Fluke Treatment Market Dynamics
  • Liver Fluke Treatment Market Size
  • Liver Fluke Treatment Market Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

The regional analysis includes:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Liver Fluke Treatment Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

Liver Fluke Treatment Market: Segmentation

Based on Drug Type, the Liver Fluke Treatment market is segmented into:

  • Triclabendazole
  • Praziquantel
  • Bithionol
  • Nitazoxanide
  • Albendazole

Based on Application, the Liver Fluke Treatment market is segmented into:

  • Human
  • Cattle
  • Sheep

Based on Distribution Channel Liver Fluke Treatment market is segmented into:

  • Government healthcare centers
  • Hospital Pharmacies
  • Retail pharmacies
  • Online Pharmacy

Report Highlights:

  • A detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current, and projected market size regarding volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies for key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Business Development

* indicates mandatory fields
Our Clients

Request Sample Request customization Request Methodology